Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC6A4 | P31645 | 1/20 | 0.49 |
| ▸ | LMNA | P02545 | 2/20 | 0.43 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.43 |
| ▸ | NPC1 | O15118 | 1/20 | 0.43 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.43 |
| ▸ | RAB9A | P51151 | 1/20 | 0.43 |
| ▸ | NFKB2 | Q00653 | 1/20 | 0.43 |
| ▸ | RELA | Q04206 | 1/20 | 0.43 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.42 |
| ▸ | POLB | P06746 | 1/20 | 0.42 |
| ▸ | MAPT | P10636 | 1/20 | 0.42 |
| ▸ | ALOX12 | P18054 | 1/20 | 0.42 |
| ▸ | HTT | P42858 | 1/20 | 0.42 |
| ▸ | AAK1 | Q2M2I8 | 2/20 | 0.40 |
| ▸ | APLNR | P35414 | 2/20 | 0.40 |
| ▸ | KCNQ3 | O43525 | 1/20 | 0.39 |
| ▸ | KCNQ2 | O43526 | 1/20 | 0.39 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.39 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.39 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1821524 | 0.84 | LMNA (0.40) | SLC6A4LMNASMN1; SMN2NPC1NFKB1 | |
| SCHEMBL31537431 | 0.84 | LMNA (0.40) | SLC6A4LMNASMN1; SMN2NPC1NFKB1 | |
| SCHEMBL29517897 | 0.82 | SLC6A4 (0.47) | SLC6A4ALDH1A1POLBAAK1APLNR | |
| SCHEMBL246292 | 0.82 | SLC6A4 (0.47) | SLC6A4ALDH1A1POLBAAK1APLNR | |
| SCHEMBL22805171 | 0.80 | SLC6A4 (0.44) | SLC6A4LMNASMN1; SMN2NPC1NFKB1 | |
| SCHEMBL22805172 | 0.80 | SLC6A4 (0.44) | SLC6A4LMNASMN1; SMN2NPC1NFKB1 | |
| SCHEMBL13443203 | 0.80 | SLC6A4 (0.44) | SLC6A4LMNASMN1; SMN2NPC1NFKB1 | |
| SCHEMBL5745812 | 0.79 | MEN1 (0.50) | SLC6A4ALDH1A1MAPTKCNQ3KCNQ2 | |
| SCHEMBL9259271 | 0.79 | MAPK1 (0.58) | LMNASMN1; SMN2NPC1RAB9AALDH1A1 | |
| SCHEMBL21057104 | 0.79 | TSHR (0.49) | SLC6A4LMNASMN1; SMN2NPC1NFKB1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 102 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20210401840-A1 | NOVEL COMPOUNDS AS MODULATORS OF PROTEIN KINASES | RHIZEN PHARMACEUTICALS AG (CH) | 2021-12-30 | — | — | US | disclosed |
| US-20210403475-A1 | NOVEL SELECTIVE PI3K DELTA INHIBITORS | RHIZEN PHARMACEUTICALS AG (CH) | 2021-12-30 | — | — | US | disclosed |
| CN-107674073-B | 3, 5-disubstituted-3H-imidazo [4,5-B ] pyridine compounds as modulators of protein kinases | 印蔻真治疗公司 | 2021-09-10 | — | — | CN | disclosed |
| EP-3828184-A1 | PYRAZOLOPYRIMIDINE DERIVATIVE AND USE THEREOF AS PI3K INHIBITOR | Medshine Discovery Inc. (CN) | 2021-06-02 | — | — | EP | disclosed |
| US-11020399-B2 | Intermediates useful in the synthesis of compounds as modulators of protein kinases | RHIZEN PHARMACEUTICALS SA (CH) | 2021-06-01 | — | — | US | disclosed |
| US-10981919-B2 | Selective PI3K delta inhibitors | RHIZEN PHARMACEUTICALS SA (CH) | 2021-04-20 | — | — | US | disclosed |
| EP-3756686-A1 | COMBINATION OF ANTI-CD20 ANTIBODY AND PI3 KINASE SELECTIVE INHIBITOR | TG Therapeutics Inc. (US) | 2020-12-30 | — | — | EP | disclosed |
| EP-3756686-A1 | COMBINATION OF ANTI-CD20 ANTIBODY AND PI3 KINASE SELECTIVE INHIBITOR | TG Therapeutics Inc. (US) | 2020-12-30 | — | — | EP | disclosed |
| US-20200323981-A1 | Combination of Anti-CD20 Antibody and PI3 Kinase Selective Inhibitor | BLUE OWL CAPITAL CORPORATION | 2020-10-15 | — | — | US | disclosed |
| US-20200323981-A1 | Combination of Anti-CD20 Antibody and PI3 Kinase Selective Inhibitor | BLUE OWL CAPITAL CORPORATION | 2020-10-15 | — | — | US | disclosed |
| US-7148226-B2 | Inhibitors of hepatitis C virus RNA-dependent RNA polymerase, and compositions and treatments using the same | AGOURON PHARMACEUTICALS, INC. (US) | 2006-12-12 | — | — | US | disclosed |
| US-7115658-B2 | Inhibitors of hepatitis C virus RNA-dependent RNA polymerase | AGOURON PHARMACEUTICALS, INC. (US) | 2006-10-03 | — | — | US | disclosed |
| EP-1697333-A1 | (3,4-DISUBSTITUTED)PROPANOIC CARBOXYLATES AS S1P (EDG) RECEPTOR AGONISTS | Merck & Co., Inc. (US) | 2006-09-06 | — | — | EP | disclosed |
| US-20060189681-A1 | INHIBITORS OF HEPATITIS C VIRUS RNA-DEPENDENT RNA POLYMERASE, AND COMPOSITIONS AND TREATMENTS USING THE SAME | AGOURON PHARMACEUTICALS, INC. | 2006-08-24 | — | — | US | disclosed |
| WO-2006010751-A1 | N-HYDROXYAMIDE DERIVATIVES AND USE THEREOF | APPLIED RESEARCH SYSTEMS ARS HOLDING N.V. (AN) | 2006-02-02 | — | — | WO | disclosed |
| EP-1597246-A2 | INHIBITORS OF HEPATITIS C VIRUS RNA-DEPENDENT RNA POLYMERASE, AND COMPOSITIONS AND TREATMENTS USING THE SAME | PFIZER INC. (US) | 2005-11-23 | — | — | EP | disclosed |
| US-20050176701-A1 | Inhibitors of hepatitis C virus RNA-dependent RNA polymerase, and compositions and treatments using the same | AGOURON PHARMACEUTICALS, INC. | 2005-08-11 | — | — | US | disclosed |
| WO-2005058848-A1 | (3,4-DISUBSTITUTED)PROPANOIC CARBOXYLATES AS S1P (EDG) RECEPTOR AGONISTS | MERCK & CO., INC. (US) | 2005-06-30 | — | — | WO | disclosed |
| WO-2004074270-A2 | INHIBITORS OF HEPATITIS C VIRUS RNA-DEPENDENT RNA POLYMERASE, AND COMPOSITIONS AND TREATMENTS USING THE SAME | PFIZER INC. (US) | 2004-09-02 | — | — | WO | disclosed |
| US-20040023958-A1 | Inhibitors of hepatitis C virus RNA-dependent RNA polymerase, and compositions and treatments using the same | AGOURON PHARMACEUTICALS, INC. | 2004-02-05 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20200323981-A1 | Combination of Anti-CD20 Antibody and PI3 Kinase Selective Inhibitor | PIK3R4, PIK3R5, PIK3R1 | SLC6A4 3324/4885LMNA 3677/4885SMN1; SMN2 4043/4885 |
| US-20210401840-A1 | NOVEL COMPOUNDS AS MODULATORS OF PROTEIN KINASES | PRKCA, PRKCH, PRKCB | SLC6A4 4695/4885LMNA 2205/4885SMN1; SMN2 2748/4885 |
| US-11020399-B2 | Intermediates useful in the synthesis of compounds as modulators of protein kinases | MAP4K2, MAP3K20, MAP3K1 | SLC6A4 4850/4885LMNA 3177/4885SMN1; SMN2 4487/4885 |
| US-20040023958-A1 | Inhibitors of hepatitis C virus RNA-dependent RNA polymerase, and compositions and treatments using the same | POLRMT, RNGTT, RNASE1 | SLC6A4 4777/4885LMNA 3489/4885SMN1; SMN2 3990/4885 |
| US-20060189681-A1 | INHIBITORS OF HEPATITIS C VIRUS RNA-DEPENDENT RNA POLYMERASE, AND COMPOSITIONS AND TREATMENTS USING THE SAME | RNASE1, RNASEH1, NSUN3 | SLC6A4 4506/4885LMNA 1494/4885SMN1; SMN2 3095/4885 |
| US-10981919-B2 | Selective PI3K delta inhibitors | PIK3CD, PIK3C2B, PIK3R5 | SLC6A4 4781/4885LMNA 1778/4885SMN1; SMN2 2841/4885 |
| US-20050176701-A1 | Inhibitors of hepatitis C virus RNA-dependent RNA polymerase, and compositions and treatments using the same | RNASE1, RNASEH1, NSUN3 | SLC6A4 4506/4885LMNA 1494/4885SMN1; SMN2 3095/4885 |
| US-20210403475-A1 | NOVEL SELECTIVE PI3K DELTA INHIBITORS | PIK3CD, PIK3R5, PIK3C2B | SLC6A4 4814/4885LMNA 2130/4885SMN1; SMN2 2724/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.